As it is frequently highly expressed in tumor tissues and metastatic cancer cells in transit via blood or lymphatic vessels [3, 6, 7], EpCAM has gained attention as a potential target for diagnostic and antibody-based immunotherapies for a spectrum of malignancies [6, 8–11]. This evidence concerns the gene EPCAM and cancer.